FOR IMMEDIATE RELEASE
Tuesday, March 20, 2012
In the past decade, scientists have made significant progress building the critical knowledge and infrastructure needed to identify and develop novel tuberculosis (TB) vaccine candidates and move the most promising ones into human clinical trials. The results of those trials, coupled with advances from other TB studies, have paved the way for the next 10 years of research on TB vaccines, a critical component of TB control efforts, note scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Their editorial, co-authored by NIAID Director Anthony S. Fauci, M.D., and Christine Sizemore, Ph.D., appears in the journal Tuberculosis to coincide with the publication of Tuberculosis Vaccines: A Strategic Blueprint for the Next Decade.
The new Blueprint on TB vaccines updates the original one, which was published in 2000 as the result of an NIH-sponsored workshop.
Since that time, TB researchers have assembled a significant pipeline of vaccine candidates and assessed them in clinical trials. However, to transform the field and help make licensure of new vaccines a reality, the editorial co-authors stress, scientists must investigate remaining fundamental questions, including the following:
NIAID, part of the team that helped to develop both iterations of the Blueprint, supports scientists working worldwide to contribute important data to these and other areas of inquiry. The authors also note that along with basic and clinical trial data, recent innovations in systems biology, genomics and bioinformatics, animal modeling, and immunologic and molecular tools will play important roles in developing safe and effective TB vaccines. The authors emphasize that close coordination among biomedical researchers, product developers, funders and TB health care programs worldwide will be essential to eventually develop and deliver new vaccines as part of the global fight against TB.
C Sizemore and AS Fauci. Transforming biomedical research to develop effective TB vaccines: The next ten years. Tuberculosis 92(S1):S2-S3 (2012).
NIAID Director Anthony S. Fauci, M.D., and Christine Sizemore, Ph.D., chief of the Tuberculosis, Leprosy and Other Mycobacterial Diseases Section in NIAID’s Division of Microbiology and Infectious Diseases, are available to discuss their editorial.
To schedule interviews, please contact Nalini Padmanabhan, (301) 402-1663, email@example.com.
For more information about the original Blueprint published in 2000, see the NIAID news release announcing its publication. For more information about NIAID’s TB research, visit the NIAID Tuberculosis Web portal.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of
infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S.
Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research,
and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH...Turning Discovery Into Health ®
back to top
Last Updated March 20, 2012
Last Reviewed March 16, 2012